Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Fineline Cube Apr 30, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Digital

ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing

Fineline Cube Nov 30, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into...

Company Policy / Regulatory

CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments

Fineline Cube Nov 30, 2023

Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...

Company Deals

Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D

Fineline Cube Nov 29, 2023

Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with...

Company Deals

Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce

Fineline Cube Nov 29, 2023

Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s...

Company Drug

Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20

Fineline Cube Nov 29, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...

Policy / Regulatory

China’s Pharma Distribution Market Grows Steadily in 2022, Driven by Retail Sales Surge

Fineline Cube Nov 29, 2023

The Ministry of Commerce (MofCOM) has released its annual statistical review of China’s pharmaceutical distribution...

Company Deals

BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal

Fineline Cube Nov 29, 2023

Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ:...

Company Deals

Blue Sail Medical and China National Medical Device Forge Strategic Partnership for Growth

Fineline Cube Nov 29, 2023

Blue Sail Medical Co., Ltd (SHE: 002382), a prominent player in China’s medical device sector,...

Company

Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services

Fineline Cube Nov 29, 2023

Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results...

Company Drug

JW Therapeutics Secures Priority Review for Carteyva in Relapsed/Refractory Mantle Cell Lymphoma

Fineline Cube Nov 29, 2023

JW Therapeutics (HKG: 2126), based in China, has announced that its CAR-T cell therapy, Carteyva...

Company Drug

Beijing Konruns Pharmaceutical Launches Phase III Study for KC1036 in Advanced Esophageal Cancer

Fineline Cube Nov 29, 2023

Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590), based in Beijing, has received approval from China’s...

Company Drug

Lee’s Pharmaceutical Secures NMPA Approval for Adasuve, Pioneering Loxapine Inhaler for Agitation

Fineline Cube Nov 29, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured marketing approval from China’s National Medical Products...

Company Medical Device

AK Medical Holdings Receives NMPA Approval for Hip Surgery Navigation System iBot

Fineline Cube Nov 29, 2023

AK Medical Holdings Ltd (HKG: 1789), a Chinese medical technology company, has announced that it...

Company Drug

Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus

Fineline Cube Nov 29, 2023

Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...

Company Deals

Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic

Fineline Cube Nov 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing...

Company Deals

Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production

Fineline Cube Nov 29, 2023

Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has...

Company Drug

Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment

Fineline Cube Nov 28, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial...

Company Drug

AbbVie’s Epcoritamab Earns EMA Review and FDA Breakthrough Designation for Follicular Lymphoma

Fineline Cube Nov 28, 2023

AbbVie’s (NYSE: ABBV) bispecific antibody (BsAb) Tepkinly/Epkinly (epcoritamab) has been accepted for review by the...

Company R&D

AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies

Fineline Cube Nov 28, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with...

Company

Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure

Fineline Cube Nov 28, 2023

German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance...

Posts pagination

1 … 430 431 432 … 659

Recent updates

  • Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
  • Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.